Blue Owl (NASDAQ: LRMR) discloses 9.99% position totaling 10.74M shares

Rhea-AI Filing Summary

Blue Owl Capital Holdings LP reported beneficial ownership of 10,739,492 shares of Larimar Therapeutics, Inc. common stock, representing 9.99% of the class. The position includes 7,120,007 shares of common stock, 975,700 shares issuable upon exercise of 9,757 call options, and 2,643,785 shares issuable upon conversion of Series A preferred stock. The reporting statement cites 103,882,937 shares outstanding as of March 17, 2026.

Insights

Institutional Ownership Analyst

Large holder reports a 9.99% stake split across common shares, options, and convertible preferred.

The filing shows 10,739,492 shares counted toward beneficial ownership, combining direct common shares, options exercisable into 975,700 shares, and convertible Series A preferred representing 2,643,785 common-share equivalents under the issuer's conversion mechanics. The 9.99% figure is calculated using 103,882,937 shares outstanding as of March 17, 2026.

Holding structure: the disclosure indicates sole voting and dispositive power over 10,739,492 shares. The statement references a conversion blocker that limits reported beneficial ownership to 9.99%; the underlying conversion could produce up to 5,000,000 common shares in absence of that blocker. Further filings may clarify timing or exercises that change this stake.

Key Figures

Beneficial ownership total: 10,739,492 shares Direct common shares: 7,120,007 shares Options exercisable into common: 975,700 shares +3 more

6 metrics

Beneficial ownership total 10,739,492 shares Reported on Schedule 13G/A

Direct common shares 7,120,007 shares Held by Reporting Person

Options exercisable into common 975,700 shares Issuable upon exercise of 9,757 call options

Convertible preferred equivalents 2,643,785 shares Issuable upon conversion of Series A preferred stock

Shares outstanding used 103,882,937 shares Outstanding as of March 17, 2026

Reported ownership percentage 9.99% Calculated based on shares outstanding as of March 17, 2026

Key Terms

conversion blocker, call options, Rule 13d-4

3 terms

conversion blocker regulatory

"conversion blocker that limits the Reporting Person's beneficial ownership to 9.99%"

call options financial

"975,700 shares of Common Stock issuable upon exercise of 9,757 call options"

A call option is a contract that gives its buyer the right, but not the obligation, to buy a specific number of shares at a predetermined price within a set time. Think of it like a refundable reservation to purchase a stock later at today’s agreed price: investors use calls to profit from expected price rises with smaller upfront cost than buying the stock outright, or to hedge and manage exposure, while the most they can lose is the amount paid for the contract.

Rule 13d-4 regulatory

"Pursuant to Rule 13d-4 of the Act, the Reporting Person declares that filing this statement shall not be deemed an admission"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/14/2026 - 04:23 PM Learn about SEC filing dates

FAQ

What percent of LRMR does Blue Owl report owning?

Blue Owl reports beneficial ownership of 9.99% of Larimar Therapeutics common stock, based on 103,882,937 shares outstanding as of March 17, 2026. The calculation includes common shares, exercisable call options, and convertible preferred stock equivalents.

How is the 10,739,492 share total composed?

The total includes 7,120,007 directly held common shares, 975,700 shares issuable upon exercise of 9,757 call options, and 2,643,785 shares issuable upon conversion of Series A preferred stock.

What is the conversion blocker mentioned in the filing?

The filing states a conversion blocker limits the Reporting Person's beneficial ownership to 9.99%. Absent the blocker, the Series A preferred could convert into 5,000,000 common shares, but the blocker constrains actual reported conversion outcomes.

Does Blue Owl have voting and disposition power over these shares?

Yes. The cover-page responses report sole voting power and sole dispositive power over 10,739,492 shares, as stated on the filing’s ownership row and Item 4 disclosures.

When was this Schedule 13G/A signed and who signed it?

The amendment is signed by Karen Hager, Chief Compliance Officer, with a signature date of May 13, 2026, as shown at the end of the filing.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 3)

Larimar Therapeutics, Inc.

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

517125100

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 517125100

1

Names of Reporting Persons

Blue Owl Capital Holdings LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 10,739,492.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 10,739,492.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

10,739,492.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.99 %

12

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person: The reported securities represent: (i) 7,120,007 shares of Common Stock; (ii) 975,700 shares of Common Stock issuable upon exercise of 9,757 call options; and (iii) 2,643,785 shares of Common Stock issuable upon conversion of Series A convertible preferred stock ("Series A Preferred Stock"). The reported percentage is calculated based on 103,882,937 shares of Common Stock outstanding as of March 17, 2026, as reported on the Issuer's 10-K filed with the Securities and Exchange Commission on March 19, 2026, as increased by (i) 975,700 shares of Common Stock issuable upon exercise of 9,757 call options and (ii) 2,643,785 shares of Common Stock issuable upon conversion of Series A Preferred Stock.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Larimar Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: Three Bala Plaza East, Suite 506, Bala Cynwyd, PA 19004
Item 2.
(a)	Name of person filing: This statement is filed by Blue Owl Capital Holdings LP, referred to herein as the "Reporting Person."
(b)	Address or principal business office or, if none, residence: 399 Park Avenue, New York, New York 10022
(c)	Citizenship: See response to row 4 on the cover page.
(d)	Title of class of securities: Common Stock, par value $0.001 per share
(e)	CUSIP No.: 517125100
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: See response to row 9 on the cover page. The reported securities include: (i) 7,120,007 shares of Common Stock; (ii) 975,700 shares of Common Stock issuable upon exercise of 9,757 call options; and (iii) 2,643,785 shares of Common Stock issuable upon conversion of 500,000 shares of Series A Preferred Stock (which would be convertible into 5,000,000 shares of Common Stock in the absence of a conversion blocker that limits the Reporting Person's beneficial ownership to 9.99%). Pursuant to Rule 13d-4 of the Act, the Reporting Person declares that filing this statement shall not be deemed an admission that the Reporting Person is a beneficial owner of the reported securities, for purposes of Section 13(d) and/or Section 13(g) or for any other purpose.
(b)	Percent of class: See response to row 11 on the cover page.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See response to row 5 on the cover page.
	(ii) Shared power to vote or to direct the vote: See response to row 6 on the cover page.
	(iii) Sole power to dispose or to direct the disposition of: See response to row 7 on the cover page.
	(iv) Shared power to dispose or to direct the disposition of: See response to row 8 on the cover page.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Blue Owl Capital Holdings LP

Signature:	/s/ Karen Hager
Name/Title:	Karen Hager / Chief Compliance Officer
Date:	05/13/2026